NIS Inhibitors
1 drugsAbout NIS
The Sodium Iodide Symporter (NIS) is a transmembrane protein that actively transports iodide into thyroid follicular cells, a process essential for thyroid hormone synthesis. NIS concentrates iodide, which is exploited in oncology to deliver targeted radiation therapy to cancerous thyroid cells.
NIS is a valuable drug target in oncology due to its ability to concentrate iodide in thyroid cells. Radioactive iodine is administered and selectively taken up by cancerous thyroid cells expressing NIS, leading to targeted radiation therapy. There is currently no genetic evidence available linking NIS to specific diseases.
NIS is targeted by one FDA-approved small molecule drug, HICON, developed by Jubilant. HICON was first approved in 2003 and is used in oncology. Further research into NIS could potentially lead to the development of novel cancer therapies or diagnostic tools.
Top NIS Drugs
Jubilant is the only company with an approved drug targeting NIS.
Low competition suggests a high barrier to entry or limited market interest, requiring careful evaluation of market potential.
NIS Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets NIS, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or peptides.
NIS Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NIS. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
NIS Drug Approval Timeline (2003 - 2003)
HICON was approved in 2003 and remains the only approved drug targeting NIS.
The lack of recent approvals indicates potential saturation or challenges in developing new NIS-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NIS. A trial counts if an approved drug acting on NIS is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.